Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Analysis of KL-6 and SP-D as disease markers in bird fancier's lung.

Authors: Janssen, R  Grutters, JC  Sato, H  Van Velzen-Blad, H  Zanen, P  Kohno, N  Welsh, KI  Du Bois, RM  Van den Bosch, JM 
Citation: Janssen R, etal., Sarcoidosis Vasc Diffuse Lung Dis. 2005 Mar;22(1):51-7.
Pubmed: (View Article at PubMed) PMID:15881280

BACKGROUND AND AIM: KL-6 and SP-D are potential serum markers in interstitial lung diseases. Their discriminative value, and ability to reflect pulmonary disease activity and prognosis in bird fancier's lung were analyzed. METHODS: We studied 49 patients, 38 unexposed and 9 exposed controls. Serum KL-6 and SP-D concentrations were measured at presentation and a second sample, taken after antigen avoidance, was available in 17 patients. Pulmonary function tests were analyzed at presentation and 2-year follow-up. RESULTS: KL-6 and SP-D were significantly elevated in patients compared to controls (p < 0.0001). ROC curve analysis revealed that both are equally useful in discriminating patients from controls. Analysis of their value as activity markers showed that both correlated with pulmonary function impairment; however, KL-6 correlated best with diffusing capacity. Evaluation of their predictive value showed that higher levels at onset were associated with improvement of diffusing capacity during follow-up. Further, it was noted that KL-6 and SP-D levels decreased after more than one month of allergen avoidance. CONCLUSIONS: KL-6 and SP-D appear useful serum markers in bird fancier's lung. Since higher levels are associated with more severe lung function impairment at presentation, and better recovery over time, we postulate that in this disease they are especially markers of disease activity.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 5131172
Created: 2011-04-21
Species: All species
Last Modified: 2011-04-21
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.